Wuhan YZY Biopharma Co., Ltd. (2496.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$3.80 (+0.00%) as of
Key statistics
- Market cap
- 736.63M
- EPS (TTM)
- -0.190
- Dividend yield
- 0.00%
- 52-week range
- 2.200 – 8.400
- Beta
- 0.48
- Revenue (TTM)
- 58.26M
- Profit margin
- -55.19%
- Volume
- 200.00
About Wuhan YZY Biopharma Co., Ltd.
Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-associated complications, and age-related ophthalmologic diseases. It develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma, and other advanced solid tumors; wAMD, DME, and other ocular neovascularization-related diseases; hemophilia; and inflammatory bowel diseases. The company was founded in 2010 and is headquartered in Wuhan, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Wuhan, China
- Employees
- 68
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.